FirstAlerts

FDA Reports Recall of Sildenafil Citrate USP Bulk Ingredient on August 19, 2026

The FDA's enforcement report dated August 19, 2026, details a Class II recall of sildenafil citrate bulk ingredient distributed nationwide, citing manufacturing deviations.

2 reports on this incident · first at Aug 26, 2026, 8:07 p.m. ET

By AI ReporterWritten Aug 26, 2026, 8:24 p.m. ET
The U.S. Food and Drug Administration's enforcement report dated August 19, 2026 (recall number ) details the recall of Sildenafil Citrate USP, a bulk ingredient used in prescription compounding. The recall, initiated August 3, 2026, was classified as , meaning the product may cause temporary or medically reversible harm and the chance of serious harm is remote, per FDA definitions. The product, manufactured by of , India, was . The recall covers 25 KG (25 x 1.00 KG bags) of Sildenafil Citrate USP, lot SDC2505001, with expiry date April 30, 2030. The reason cited was CGMP deviations noted during an FDA inspection. The agency's database records no other enforcement action by this firm. Consumers who have this product should check the lot number and expiry date on the label. The FDA considers the recall carried out, but the status remains .

Earlier reports

  1. Aug 26, 2026, 8:07 p.m. ETFirst report

    FDA Recalls Sildenafil Citrate USP Bulk Ingredient Over Manufacturing Deviations

    The U.S. Food and Drug Administration (FDA) announced a Class II recall of Sildenafil Citrate USP, a bulk active pharmaceutical ingredient used in prescription compounding, on August 19, 2026. The recall, initiated August 3, 2026, covers 25 kg (25 x 1.00 kg bags) distributed nationwide in the USA. The product is labeled with lot SDC2505001, expiry April 30, 2030, and NDC 85702-001-08.

    The recall was prompted by current Good Manufacturing Practice (CGMP) deviations noted during an FDA inspection, according to the FDA enforcement report (recall number D-0763-2026). The FDA classifies this as a Class II recall, meaning the product may cause temporary or medically reversible harm, with the chance of serious harm remote.

    The product is a bulk ingredient sold to licensed formulators and compounding pharmacies, not directly to consumers. The FDA's enforcement database lists no other enforcement actions by Shoolin Pharma Chem LLP. The recall is ongoing.

Was this report accurate and useful?

Sources

Revision history

  1. Version 127 Aug 2026, 00:07current

    First published.

  2. Version 127 Aug 2026, 00:24current

    First published.

How we work

This site models an investigative reporter rather than a wire desk. The aim is the most complete, accurate and timely account we can assemble — all three, not a trade between them. Reports go out within minutes of the coverage they are built from, carrying context a newsroom would otherwise need a day and a records request to gather: what has happened at this place before, what the operator’s record is, which aircraft it actually was.

Reports are built from primary sources — accident and court records, official registries, weather observations, agency statements — and from reputable news organisations, each named where their reporting is used. Facts are extracted before anything is written, and every one must be supported by a quotation found in the source itself; the model that writes the report is given only those verified facts and never sees the article, so it cannot introduce a detail no source stated.

Where sources disagree we publish the disagreement, attributed, rather than picking a figure. Where a fact comes from a record rather than a reporter, we say so, and the language matches: an instrument reading is never described as something anyone confirmed. Some things are deliberately withheld — a suspect is not named until an agency names them on the record, victims until families or officials release them — and corrections appear as visible revisions, never as silent edits.

None of that makes a report true. A quotation check proves a source said something, not that it was right, and an automated system can be confidently wrong in ways the checks do not catch. If something here is wrong, the feedback above is how it gets found. The full methodology, including what we refuse to publish.